Changes in Hong Kong stocks | CRO concept stocks are rising today, leading reports, performance verification, industry sentiment, and the release of AI pharmaceuticals potential is expected to drive demand

The Zhitong Finance App learned that CRO concept stocks generally rose today, and Yao Ming Kangde's stock price reached a record high. As of press release, Gloria Young (06821) rose 7.26% to HK$122.7; Zhaoyan Pharmaceutical (06127) rose 6.54% to HK$26.72; Kingsley Biotech (01548) rose 4.66% to HK$26.04; Pharmaceuticals Kangde (02359) rose 3.65% to HK$204.6; and Kanglong Chemical (03759) rose 3.43% to HK$30.74.

According to the news, various overseas CXO companies have recently released their 2026 interim reports. Among them, Yao Ming Kangde's interim results have greatly exceeded market expectations, and the 2026 full-year performance guidelines have been raised comprehensively. It is worth noting that AI pharmaceuticals have the potential to unleash or reshape the future picture of pharmaceuticals. Guojin Securities believes that a large number of candidate molecules produced by AI virtual design still need to be verified by wet experiments such as synthesis, pharmacology, and toxicology, which directly drives the increase in demand for upstream and CXO outsourcing.

Bank of America Securities recently released a research report saying that benefiting from strong global and Chinese biotechnology primary market financing performance in the first half of the year, and continued active external licensing transactions for innovative drugs, it is expected that R&D activities will further accelerate, and Chinese CRO/CDMO companies are expected to benefit. The bank raised the assumption that the industry's terminal growth rate will increase from 1% to 3%, and raised the target prices of many CXO companies.